3 January 2019 - Managed entry agreements enable payers to subsidise access to new medicines while addressing uncertainties. 

Uncertainties may relate to the criteria for decision-making articulated in decision-making frameworks. The study's aim was to determine if there was any association between the type of managed entry agreements (MEAs) and criteria considered during decision-making.

All medicines with MEAs listed on the Australian national subsidy scheme between 2012-2016 were identified. Data were extracted on the types of MEA and information related to the criteria considered in decision-making for each medicine and its associated indication (i.e. a medicine-indication pair).

Read International Journal of Technology Assessment in Health Care article